Guggenheim Capital LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,462 shares of the medical research company's stock after purchasing an additional 1,841 shares during the period. Guggenheim Capital LLC's holdings in Thermo Fisher Scientific were worth $21,129,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of TMO. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $25,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $30,000. Keystone Global Partners LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $31,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $35,000. Finally, Navigoe LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $37,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,896 shares of company stock worth $13,603,438 over the last ninety days. Corporate insiders own 0.33% of the company's stock.
Analyst Ratings Changes
Several research analysts recently weighed in on the company. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. UBS Group lifted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Finally, Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.
Read Our Latest Stock Report on TMO
Thermo Fisher Scientific Stock Performance
Shares of NYSE:TMO opened at $488.93 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business's 50 day moving average price is $446.71 and its 200-day moving average price is $455.47. The firm has a market capitalization of $184.63 billion, a PE ratio of 28.28, a P/E/G ratio of 2.62 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.